Coloplast A/S (OTCMKTS:CLPBY) Stock Lifted to “Strong-Buy” by Barclays

Coloplast A/S (OTCMKTS:CLPBY) was upgraded by equities researchers at Barclays from a “hold” rating to a “strong-buy” rating in a research report issued on Tuesday, Zacks reports.

Coloplast A/S Stock Performance

OTCMKTS CLPBY opened at $7.80 on Tuesday. The company has a current ratio of 1.56, a quick ratio of 0.94 and a debt-to-equity ratio of 1.51. The firm’s fifty day moving average price is $6.85 and its two-hundred day moving average price is $6.79. Coloplast A/S has a 1 year low of $5.64 and a 1 year high of $9.57. The firm has a market capitalization of $17.59 billion, a P/E ratio of 37.16, a price-to-earnings-growth ratio of 2.85 and a beta of 0.10.

Coloplast A/S (OTCMKTS:CLPBY) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported $0.09 EPS for the quarter, meeting analysts’ consensus estimates of $0.09. The company had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.12 billion. Coloplast A/S had a net margin of 10.57% and a return on equity of 42.25%. As a group, research analysts anticipate that Coloplast A/S will post 0.40 EPS for the current year.

Coloplast A/S Company Profile

Coloplast A/S is a Denmark-based medical technology company that develops, manufactures and markets products designed to help people manage intimate health conditions. Its core businesses include ostomy care, continence care, wound and skin care, and interventional urology. The company’s products are used by patients and healthcare professionals in hospitals, clinics and home-care settings.

Coloplast was founded in Denmark in 1957 after nurse Elise Sørensen helped develop an adhesive ostomy bag for her sister, who had undergone surgery.